History of allergy or hypersensitivity to study drug components. Prior malignancy treated with anticancer therapy (including systemic chemotherapy, radiation and/or surgery) within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. History of organ transplant that requires use of immune suppressive agents.
Second malignancy (solid or hematologic) within the past  years except locally curable cancers that have been apparently cured
Prior malignancy within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, or carcinoma in situ of the cervix or breast or bladder.
Prior malignancy active within the previous  years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured
Prior malignancy active within the previous  years. Patients with locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation) are eligible.
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast
Prior malignancy active within the previous  years except for patients prior diagnosis of sarcoma and locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation).
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Prior malignancy active within the previous  years. Patients with locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation) are eligible
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, prostate cancer without evidence of prostate-specific antigen (PSA) progression or carcinoma in situ such as the following: gastric, prostate, cervix, colon, melanoma, or breast for example
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast or low risk Gleason  prostate cancer
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized prostate cancer; if patients have another malignancy that was treated within the last  years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within  years is less than %, as determined by an expert in that particular malignancy at MD Anderson Cancer Center and after consultation with the principal investigator
Prior malignancies active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, breast, or etc.
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured
Prior non-melanoma malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured
Prior malignancy active within the previous  years except for locally curable cancers
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured
Prior non-melanoma malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast
Prior malignancy active within the previous  years except for tumor for which a patient is enrolled in the study, and locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.
Prior malignancy active within the previous  years except for patient's prior diagnosis of melanoma and locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation)
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized prostate cancer; if patients have another malignancy that was treated within the last  years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within  years is less than %, as determined by an expert in that particular malignancy at MD Anderson Cancer Center and after consultation with the Principal Investigator
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured
Prior malignancy active within past  years, except for locally curable cancers
Prior active malignancy within the previous  years except for locally curable cancers such as basal or squamous cell cancer superficial bladder, low risk prostate cancer, breast, or cervix cancer unless it is believed the malignancy will not affect the study outcome
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Prior active malignancy within the previous  years except for locally curable cancers such as basal or squamous skin cancer, superficial bladder, low risk prostate cancer, breast, or cervix cancer; if other prior malignancy was active within prior  years, enrollment requires approval of a principal investigator
Subjects with a history of prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured
Other active malignancy =<  years prior to registration except for locally curable cancers that have been in apparently cured, such as basal or squamous cell skin cancer, prostate cancer without evidence of prostate-specific antigen (PSA) progression or carcinoma in situ such as the following: gastric, cervix, colon, melanoma or breast for example
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized prostate cancer; if patients have another malignancy that was treated within the last  years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within  years is less than %, as determined by an expert in that particular malignancy at Monroe Dunaway (MD) Anderson Cancer Center and after consultation with the principal investigator
Prior malignancy active within the previous  years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Prior malignancy, active within the last  years, except for locally curable cancers which have been apparently cured